Background: Sphingosine-1-phosphate receptor-2, S1P 2 , is expressed in vascular
INTRODUCTION
Sphingosine-1-phosphate (S1P) has been identified as an important regulator of vascular and immune functions.
1, 2 S1P is synthesized by sphingosine kinases-1 and -2 in a wide variety of cells. 3 Plasma S1P, which is present at the concentration of ~10 -6 M, is derived from erythrocytes, vascular endothelial cells (EC) and other cells. [4] [5] [6] Most of the biological activities of S1P are mediated by the S1P-specific G protein-coupled receptor family S1P 1~ S1P 5 . 7 Among these, S1P 1 , S1P 2 and S1P 3 are widely expressed major receptor subtypes. EC in culture express readily detectable levels of S1P 1 and S1P 3 whereas S1P 2 expression is much lower or undetectable. 8, 9 However, we recently observed by analyzing LacZ-knockin mice at the S1pr2 locus that EC in a variety of organs express S1P 2 in vivo. 10 S1P 1 and S1P 2 exert distinct effects on cell responses, including migration and proliferation, through the preferential coupling to G i and G 12/13 , respectively.
11
Platelet-activating factor (PAF), histamine and leukotrienes are edematogenic mediators that disrupt vascular barrier integrity, which is sustained mainly by the endothelial adherens junction (AJ) comprising VE-cadherin and its associated proteins. 12 In anaphylaxis, these edematogenic mediators are released mainly from mast cells through antigen engagement of mast cell-associated IgE and act on vascular endothelium and smooth muscle to cause severe vascular leakage and hypotension. 13 To establish novel therapies for anaphylaxis, it is important to better understand the pathophysiological mechanisms underlying vascular barrier disruption. Both in vitro and in vivo studies have documented that S1P maintains vascular endothelial barrier function via endothelial S1P 1 . 14, 15 A subsequent study showed that plasma S1P is required to prevent vascular leakage in anaphylaxis after antigen challenge or injections of PAF and histamine. 16 Thus, the plasma S1P-endothelial S1P 1 axis plays Cui 7 a central role in maintaining vascular barrier integrity. 17 In contrast to S1P 1 , pharmacological blockade of S1P 2 was reported to reduce histamine-induced vascular leakage. 18 More recently, it has been shown that genetic deletion of S1pr2 attenuated vascular leakage and hypothermia in anaphylaxis after antigen challenge. 19 
S1pr2
deletion was accompanied by diminished elevation of plasma histamine and cytokines after antigen challenge, suggesting that stimulation of mast cell activation by S1P 2 is a determinant of vascular hyperpermeability and anaphylaxis. Unlike this report, however, another group showed that S1P 2 was rather vital for recovery from histamine-induced hypothermia through regulating vascular tone and histamine clearance, which suggests that S1P 2 exerts a protective effect against anaphylaxis at a site distal to mast cell activation. 20, 21 Thus, the in vivo role of S1P 2 in anaphylaxis is not yet fully understood.
Previous studies demonstrated that endothelial nitric oxide (NO) synthase (eNOS or NOS3)-derived NO is involved in an increase of vascular permeability caused by PAF and vascular endothelial growth factor-A (VEGF). [22] [23] [24] The activity of the calmodulin-dependent enzyme eNOS is stimulated by an increase in intracellular free Ca 2+ , interaction with regulatory proteins, and phosphorylation mediated largely by Ca 2+ -independent protein kinases including Akt and protein kinase A. 25 Phosphorylation of eNOS sensitizes eNOS to Ca 2+ , resulting in augmented activation of eNOS. Most edematogenic mediators, including PAF and histamine, act through G protein-coupled receptors. Importantly, anaphylactic shock has been shown to depend on eNOS activation mediated by endothelial G q/11 and phosphatidylinositol 3-kinase (PI3K)-Akt. 26, 27 We recently found that endogenous S1P 2 mediates inhibition of Akt in EC, 10 unlike S1P 1 which stimulates eNOS via Akt. 28 These observations raise the possibility that S1P 2 might suppress eNOS through inhibition of Akt, exerting a Cui 8 rescue effect on vascular hyperpermeability.
In the present study, we tested this hypothesis by determining how genetic Nos3 deletion and pharmacological eNOS blockade affected S1P 2 -mediated effects on vascular hyperpermeability in anaphylaxis in mice. Our results indicate that S1P 2 protects mice from vascular barrier disruption elicited by either antigen challenge or PAF injection and that this protective effect of S1P 2 is mediated through suppression of anaphylaxis-associated eNOS stimulation. These observations provide the basis for targeting S1P 2 as a novel treatment of anaphylaxis.
Cui 9
METHODS
Supplemental information can be found in the Methods section in this article's Online
Repository.
Mice
All animal experiments were conducted according to the Fundamental Guidelines 
RESULTS

S1P 2 protects mice from vascular hyperpermeability in anaphylaxis
We studied how S1P 2 affected vascular hyperpermeability and mortality using two models of active systemic anaphylaxis, which predominantly depends on PAF. 29 Mice had been sensitized with bovine serum albumin (BSA) or ovalbumin (OVA) and challenged with these antigens. After BSA challenge, S1pr2 -/-mice displayed greater extravasation of i.v. injected Evans blue in the lung compared with WT mice (Fig 1, A and B). Consistent with this, S1pr2 -/-mice showed higher hematocrit (HCT) due to augmented plasma leakage compared with WT mice (Fig 1, C) . Evans blue leakage under saline administration was similar in S1pr2 -/-and WT mice, suggesting that basal vascular permeability was not altered in S1pr2 -/-mice. S1pr2 -/-mice began to die within 10 min after the antigen challenge and all S1pr2 -/-mice died by 30 min, whereas WT mice started to die as late as 25 min and 45% of WT mice survived the antigen challenge at 60 min (Fig 1, D) . Similarly, in OVA-sensitized S1pr2 -/-mice, challenge with OVA augmented Evans blue leakage and HCT elevation compared with those in WT mice (Fig E1) .
We next studied the vascular permeability responses to i.v. injection of the anaphylactic mediator PAF. S1pr2 -/-mice showed greater PAF-induced extravasation of Evans blue dye in the lung than did WT mice ( Fig E2, A and B ). Histological analysis of the lungs showed more pronounced accumulation of perivascular fluid in S1pr2 -/-mice after PAF injection, compared with WT mice (Fig E2, C) . S1pr2 -/-mice exhibited higher HCT compared with that of WT mice at 10 min after PAF injection (Fig E2, D) . Consequently, survival after PAF injection was severely impaired in S1pr2 -/-mice: 90% of WT mice survived PAF challenge whereas less than 10% of S1pr2 -/-mice survived (Fig E2, E) . We also analyzed the effect of PAF on dermal Cui 11 vascular permeability in S1pr2 -/-and WT mice using a Miles assay. Basal vascular permeability was similar in S1pr2 -/-and WT mice (Fig E2, F were similar to those in S1pr2 -/-mice. In these experiments, we anesthetized mice for a very short time (~1 min) with ether. In the non-anesthetized condition, we observed essentially the same exaggerated responses in HCT and death after PAF injection in S1pr2 -/-mice compared with WT mice (Fig E4) . These data indicate that S1pr2 -/-mice show enhanced vascular permeability with increased mortality in anaphylaxis.
Akt/eNOS activation is augmented in aorta and lung of S1pr2 -/-mice after PAF challenge S1pr2 -/-and WT mice, which received saline injection, showed similar levels of basal phosphorylation of Akt ( and WT mice but with a greater increase in S1pr2 -/-mice (Fig 2, A) . In contrast, PAF-induced activation of ERK or p38MAPK was not different between S1pr2 -/-and WT mice (data not shown). Notably, PAF injection increased eNOS phosphorylation in aorta from both mouse groups with a greater degree of stimulation in S1pr2 -/-mice (Fig 2, B) . Cui 12 Similarly to aorta, PAF increased phosphorylation in Akt and eNOS in lung from both S1pr2 -/-and WT mice with greater degrees of stimulation in S1pr2 -/-mice (Fig 2, C and D). NO synthesized by eNOS stimulates the formation of cyclic GMP (cGMP) in vascular wall. The basal level of cGMP in aorta was similar between S1pr2 -/-and WT mice (Fig 2, E) . PAF injection induced a larger increase in aortic cGMP level in S1pr2 -/-mice than in WT mice. These observations raise the possibility that the exaggerated increase in vascular permeability in S1pr2 -/-mice might be due to augmented activation of the Akt/eNOS signaling pathway and generation of NO in the vasculature.
Pharmacological inhibition of NO synthase or genetic deletion of Nos3 protect
S1pr2 -/-mice from vascular hyperpermeability in anaphylaxis
Administration of Nω-L-nitro-argininemethyl ester (L-NAME) 3 h before PAF injection prevented the exaggerated HCT elevation after PAF challenge in S1pr2 -/-mice ( Fig E5, A) . L-NAME also protected S1pr2 -/-mice against PAF-induced lethality (Fig E5, B) . These observations suggest that NO is involved in PAF-induced vascular leakage and lethality in S1pr2 -/-mice. To elucidate the role of eNOS in exaggerated PAF-induced vascular leakage in S1pr2 -/-mice, we crossed S1pr2 -/-mice with Nos3
-/-mice to generate S1pr2 -/-;Nos3 -/-compound mutant mice. The HCT after PAF injection in S1pr2 -/-;Nos3 -/-mice was lower than that in S1pr2 -/-mice and was not different from that in WT mice or Nos3 -/-mice (Fig 3, A) . Thus, augmentation of the PAF-induced HCT elevation in S1pr2 -/-mice was abolished by Nos3 deficiency. Consistently,
S1pr2
-/-;Nos3 -/-mice were almost completely rescued from PAF-induced lethality (Fig   3, B) .
We also studied the effects of Nos3 deficiency on vascular responses in Cui 13 anaphylaxis after BSA challenge. The magnitude of the increase in plasma histamine level after antigen challenge was similar in WT, S1pr2
, and S1pr2 -/-;Nos3 -/-mice ( Fig E6, A) . The HCT at 10 min after antigen challenge in S1pr2 -/-;Nos3 -/-mice was lower than that in S1pr2 -/-mice and similar to that in WT mice and Nos3 -/-mice (Fig 3, C) . These observations suggest that eNOS in the vascular endothelium is responsible for S1pr2 deficiency-induced aggravation of vascular hyperpermeability in anaphylaxis. We studied the hypotensive response to an antigen challenge in these mutant mice. A previous study 30 documented that in S1pr2 -/-mice, the in vivo pressor response and the in vitro vascular contractile response to phenylephrine were diminished, the latter of which was endothelium-dependent. S1pr2 -/-mice showed significantly lower steady state systolic and diastolic blood pressure than WT mice while both Nos3 -/-mice and S1pr2 -/-;Nos3 -/-mice displayed higher systolic blood pressure than WT mice (Table E1) . Antigen challenge induced a rapid drop in blood pressure to a level of ∼40 mmHg in anesthetized WT mice, and hypotension persisted for more than 40 min (Fig 3, D) . In S1pr2 -/-mice, blood pressure declined more rapidly and became unmeasurably low, leading to death within 25 min. Under the same condition, S1pr2 -/-;Nos3 -/-mice and Nos3 -/-mice showed only a mild, transient reduction in blood pressure and recovered by 50 min. These observations indicate that S1pr2 -/-mice exhibit severe fatal circulatory shock and that deletion of Nos3 gene protects both S1pr2 -/-and WT mice from anaphylactic shock. Antigen challenge in WT mice induced a decline in core body temperature (mean change of -1.6°C at 20 min) (Fig E6, B) . S1pr2 -/-mice displayed more severe hypothermia compared with WT mice. S1pr2 -/-;Nos3 -/-mice and Nos3 -/-mice exhibited only a mild, transient decrease in body temperature, which was less marked compared with that in WT mice.
Consistent with all these data, S1pr2 -/-;Nos3 -/-mice were protected from antigen Cui 14 challenge-induced lethality: S1pr2 -/-single mutant mice started to die at 8 min after antigen challenge with 85% mortality at 60 min, whereas S1pr2 -/-;Nos3 -/-mice began to die at 45 min and mortality at 60 min was 38% (Fig 3, E) . Nos3 -/-single mutant mice were also protected from antigen challenge-induced lethality as reported previously.
26
S1P 2 negatively regulates Akt-eNOS pathway in vascular EC
In lung EC (MLEC) from WT mice, PAF stimulated phosphorylation of both Akt and eNOS (Fig 4, A and B) . S1P alone did not affect phosphorylation of Akt or eNOS but rather reduced PAF-induced phosphorylation of eNOS in WT MLEC. In contrast to WT MLEC, S1P by itself stimulated phosphorylation of Akt and eNOS in S1pr2
MLEC. This is most likely because S1P 1 , which is a major S1P receptor in S1pr2
MLEC, mediated S1P-induced phosphorylation of Akt and eNOS whereas S1P 2 counteracted S1P 1 -mediated phosphorylation of Akt and eNOS in WT MLEC.
Furthermore, PAF stimulated phosphorylation of Akt and eNOS to a greater degree in
S1pr2
-/-MLEC compared with WT MLEC. Unlike WT MLEC, S1P did not reduce PAF-induced phosphorylation of Akt and eNOS in S1pr2 -/-MLEC, so that phosphorylation of Akt and eNOS in S1pr2 -/-MLEC stimulated with S1P plus PAF was substantially greater than in WT MLEC. We examined how S1P 2 affected the production of NO in MLEC. In MLEC isolated from WT mice, either PAF or VEGF but not S1P stimulated the generation of NO (Fig 4, C) . In S1pr2 -/-MLEC, PAF and VEGF stimulated NO production to a greater degree compared with WT EC.
Moreover, S1P by itself modestly stimulated NO production in S1pr2 -/-MLEC, which was consistent with the results of eNOS phosphorylation (Fig 4, B) . In addition, S1P
slightly enhanced PAF-induced NO production in S1pr2 -/-MLEC. These observations Cui 15 suggest that S1P 2 exerts inhibitory effects on NO production in EC through reducing phosphorylation of Akt and eNOS.
S1P 2 contributes to maintaining AJ through inhibiting PAF-induced
S-nitrosylation of β-catenin
NO mediates disruption of endothelial AJ, which comprise VE-cadherin and intracellular associated proteins including β-catenin and p120 catenin, 12 and increases vascular permeability. 22, 23, 25 Recent studies 31, 34 demonstrated that VEGF stimulation of eNOS induced S-nitrosylation of β-catenin, leading to disassembly of AJ complexes. We examined how S1P 2 influenced PAF-induced disassembly of AJ and
S-nitrosylation of β-catenin in a monolayer of MLEC. Immunofluorescent staining
with anti-VE-cadherin and anti-β-catenin antibodies showed that VE-cadherin and β-catenin were uniformly distributed at cell-cell contacts in both WT and S1pr2
MLEC in a non-treated condition, indicating that AJ were formed (Fig 5, A) . PAF treatment resulted in a discontinuous, zigzag pattern of staining of both VE-cadherin and β-catenin in both WT and S1pr2 -/-MLEC, indicating disruption of AJ.
PAF-induced disruption of AJ was more severe in S1pr2 -/-MLEC than in WT MLEC.
Pretreatment with L-NAME almost totally prevented disruption of AJ in both WT and S1pr2 -/-MLEC. We analyzed S-nitrosylation of β-catenin in MLEC treated with PAF and S1P in the presence and absence of L-NAME. In WT EC, PAF plus S1P tended to increase S-nitrosylation of β-catenin but not significantly (Fig 5, B) . In contrast, PAF plus S1P substantially increased S-nitrosylation of β-catenin in S1pr2 -/-MLEC.
L-NAME abolished S-nitrosylation of β-catenin induced by PAF plus S1P in both WT
and S1pr2 -/-MLEC. These results suggest that S1P 2 inhibits PAF-induced disassembly of AJ through mechanisms involving inhibition of NO production and thereby Cui 16 prevention of S-nitrosylation of β-catenin.
Cui 17
DISCUSSION
The present study provides evidence supporting that S1P 2 is protective against acute vascular barrier disruption, based on the composite results obtained in two anaphylaxis models of antigen challenge and PAF injection. Our study also revealed the mechanisms underlying the protective effect of S1P 2 : S1P 2 suppressed harmful robust activation of eNOS, which plays a key role in vascular leakage in anaphylaxis.
Thus, our study identified the role of a novel endothelial signaling pathway comprising S1P 2 -Akt inhibition-eNOS inhibition, which plays a protective role against vascular barrier-disruption and may represent a promising new target for treating vascular hyperpermeability.
We studied the effects of S1pr2 deficiency on acute vascular barrier disruption in active anaphylaxis and PAF injection. In the active anaphylaxis model, our data demonstrated that S1pr2 deficiency exacerbated vascular leakage, hypotension, hypothermia and lethality without causing an increase in plasma histamine level (Figs 1 and 3, and Fig E6) . Moreover, S1pr2 exacerbated vascular leakage and lethality provoked by injection of the anaphylactic mediator PAF (Fig E2) . These results together imply that S1P 2 alleviates acute vascular permeability largely by acting at a site distal to the release of anaphylactic mediators from mast cells; i.e., very likely at the vasculature itself. Our observations are consistent with the studies by Olivera et al., 20, 21 which showed that histamine injection-induced hypothermia and hypotension were aggravated in S1pr2 -/-mice, but are not consistent with that by Oskeritzian et al., 19 which showed that S1pr2 deficiency alleviated vascular leakage and hypothermia after antigen challenge, contrasting to our study. The findings by
Oskeritzian et al. 19 also differ from our observations, in that PAF or histamine injection-induced vascular leakage and hypothermia were not different between back-crossing once or twice of C57BL/6 x 129/Ola with C57BL/6 (our study)).
The present study demonstrated that endothelial S1P 2 inhibits eNOS (Fig 4) .
S1pr2 deficiency de-inhibits eNOS in the vasculature in vivo (Fig 2) . NO generated by eNOS is involved in vascular hyperpermeability in response to pro-inflammatory mediators such as PAF and VEGF. [22] [23] [24] Moreover, acute hypotension and lethality after antigen challenge and PAF injection entirely depend on the PI3K/Akt/eNOS pathway. 26 Our results also showed that inhibition of eNOS action by genetic or pharmacological manipulation in S1pr2 -/-mice markedly improved vascular leakage, hypotension and survival rate after antigen challenge, thus abrogating the effects of S1pr2 deficiency (Fig 3 and Fig E5) . All these observations together indicate that S1P 2 provides a protective effect against vascular barrier disruption largely by suppressing eNOS.
NO regulates many biological processes including vasorelaxation, through stimulating soluble guanylate cyclase and cGMP production. 32 However, the previous study 26 showed that a specific inhibitor of soluble guanylate cyclase or genetic deletion of soluble guanylate cyclase-α1, a major isoform in the vasculature, did not protect mice from PAF-induced lethality, suggesting that NO might mediate shock in a manner independent of cGMP. In addition to guanylate cyclase-cGMP, NO may affect biological processes through causing S-nitrosylation of proteins. 33 AJ control endothelial barrier function. 12 Recent studies showed that VEGF induced Cui 19 S-nitrosylation of β-catenin, resulting in the dissociation of β-catenin from VE-cadherin and disassembly of AJ complexes. 31, 34 In pulmonary EC, PAF and S1P
induced S-nitrosylation of β-catenin with disassembly of VE-cadherin and β-catenin at cell-cell contacts, which was augmented by S1pr2 deficiency (Fig 5) . Of note, pharmacological blockade of eNOS restored the aggravation of S-nitrosylation of β-catenin and AJ disassembly by S1pr2 deficiency. Therefore, our data together with these recent observations indicate that S1P 2 exerts a protective effect on barrier functions through mechanisms involving inhibition of S-nitrosylation of β-catenin and consequent disassembly of the AJ.
Akt is a major Ca 2+ -independent eNOS-activating protein kinase. 35 S1pr2 deficiency augmented activation of Akt as well as eNOS in the vasculature (Fig 2) .
Therefore, it is likely that increased Akt activity at least in part mediates enhanced eNOS phosphorylation in S1pr2 -/-mice. Endogenously expressed S1P 2 is nearly exclusively coupled to G 12/13 and downstream Rho. 36 S1P 2 was previously shown to stimulate 3'-specific phosphatase of phosphoinositides, "phosphatase and tensin homolog deleted from chromosome 10 (PTEN)", via Rho kinase. 37 Phosphatidylinositol-3,4,5-P 3 generated by PI3K mediates Akt stimulation. S1P 2 -mediated stimulation of PTEN decreases the cellular level of phosphatidylinositol-3,4,5-P 3 , thereby resulting in inhibition of Akt activation. 37 The previous gene knockout study by Korhonen et al. 27 showed that endothelial G q/11 -mediated signaling is crucially involved in NO formation and vascular barrier disruption induced by PAF and other mediators. G q/11 mediates activation of the calmodulin-dependent enzyme eNOS through both mechanisms of Ca 2+ mobilization
and Akt-mediated eNOS phosphorylation. 35 Hence, the study by Korhonen et al. 27 and our study together suggest that the PAF receptor, which is a G q/11 -coupled receptor, Cui 20 mediates an increase in vascular permeability through eNOS stimulation whereas S1P 2 counteracts this G q/11 -mediated action through G 12/13 -mediated suppression of the Akt-eNOS pathway.
Among the S1P receptors, S1P 1 has been shown to potentiate endothelial barrier integrity in vivo and in vitro. 8, 14, 38 A recent study using sphingosine kinases-null mice indicated that plasma S1P is required for vascular integrity. 16 Furthermore, administration of synthetic S1P 1 agonists, which powerfully induce downregulation of S1P 1 , but also that of S1P 1 antagonists induced pulmonary edema. 15, 17, 39 Moreover, S1P 1 stimulates eNOS phosphorylation through G i -PI3K-Akt, unlike S1P 2 . 40 However, the stimulatory effect of S1P 1 on phosphorylation of Akt and eNOS seems to be counteracted by S1P 2 in WT EC, as suggested by our observation that S1P increased phosphorylation of Akt and eNOS in S1pr2-deficient EC but not WT EC (Fig 4) . These distinct signaling properties likely underlie the differential roles of S1P 1 and S1P 2 in the regulation of barrier integrity: S1pr2 deficiency does not affect baseline vascular permeability but prevents enhanced vascular leakage after antigen challenge or injections of PAF and histamine (Figs 1, and Figs E1 and E2). 20 Consistent with this is the previous observation that baseline permeability was not affected by the presence or absence of eNOS. 22, 23 Different from S1P 2 , S1P 1 maintains not only constitutive barrier integrity but protects against barrier disruption caused by anaphylaxis and inflammation. 15, 16, 39 It is likely that S1P 1 protects the integrity of AJ through a mechanism different from eNOS-NO regulation. Thus, these observations together with the previous Cui 21 observations 27 suggest that receptor signaling mediated by G q/11 , G i and G 12/13 play distinct critical roles in triggering, preventing and limiting vascular leakage.
We have demonstrated that S1P 2 suppresses stimulation of eNOS and NO generation in EC through inhibition of Akt during anaphylaxis. As a result, S1P 2 protects against the disassembly of endothelial AJ by inhibiting S-nitrosylation of β-catenin, and thereby vascular leakage. An S1P 2 -selective agonist may have a distinct clinical benefit over an S1P 1 -selective agonist as a therapeutic for anaphylaxis. challenge of S1pr2 +/+ and S1pr2 -/-mice with or without Nos3 deficiency. with S1P (30 nM) plus L-NAME (1 mM) or S1P alone for 10 min and then stimulated with PAF (100 nM) for 30 min, followed by analysis using the biotin-switch method and western blotting with anti-β-catenin antibody. Left: representative blots. Right:
quantified data of S-nitroso-β-catenin.
